Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/4424

TDMS Study 88127-06 Pathology Tables

NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01
Route: SKIN APPLICATION                                                                                           Time: 08:15:23

                                                         Final #1/Mice




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  3524-68-3

       Lock Date:  06/16/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      2                         3            3            2            3           
    Moribund Sacrifice                                 1            1                                                   3           
  Survivors                                                                                                                         
    Terminal Sacrifice                                12           14           12           12           13            9           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Salivary Glands                                                                                                     (1)          
      Carcinoma                                                                                                         1 (100%)    
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          2 (13%)      4 (27%)      5 (33%)      4 (27%)      6 (40%)      3 (20%)     
      Squamous Cell Papilloma, Multiple                3 (20%)                                3 (20%)      1 (7%)       1 (7%)      
   Tooth                                              (4)                       (3)          (3)          (1)                       
      Odontogenic Tumor                                4 (100%)                  3 (100%)     2 (67%)      1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Adrenal Medulla                                    (15)         (15)         (15)         (14)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
      Pheochromocytoma Benign                                                    1 (7%)                                             
   Pituitary Gland                                    (15)         (15)         (14)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Uterus                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                                       
   Vagina                                                                                                 (1)                       
      Squamous Cell Papilloma                                                                              1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (15)         (14)         (13)         (12)         (15)         (14)         
      Mediastinal, Leukemia Erythrocytic               1 (7%)                                                                       
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)         (13)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (8%)      
   Lymph Node, Mesenteric                             (14)         (15)         (15)         (14)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Thymus                                             (15)         (15)         (15)         (14)         (14)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma, Multiple                                                                    1 (7%)                   
      Skin, Site of Application, Keratoacanthoma                                                                        1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                                                                     1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           3 (20%)                               
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                    1 (7%)       7 (47%)     12 (80%)     13 (87%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             9           4           6          13          13          14               
     Total Primary Neoplasms                           10           4          10          20          22          21               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           4           6          11          13          13               
     Total Benign Neoplasms                             5           4           7          17          21          18               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1                                   1                       3               
     Total Malignant Neoplasms                          1                                   1                       3               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  4                       3           2           1                           
     Total Uncertain Neoplasms                          4                       3           2           1                           
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      3                                                   2            5           
    Moribund Sacrifice                                              1                                      1                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                12           14           15           15           12           10           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
   Salivary Glands                                    (1)          (1)                       (1)                       (1)          
      Carcinoma                                        1 (100%)     1 (100%)                  1 (100%)                  1 (100%)    
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          2 (13%)      3 (20%)      5 (33%)      5 (33%)      5 (33%)      3 (20%)     
      Squamous Cell Papilloma, Multiple                4 (27%)      1 (7%)                    3 (20%)                   2 (13%)     
   Tooth                                              (2)                       (3)          (1)          (3)          (2)          
      Odontogenic Tumor                                2 (100%)                  3 (100%)     1 (100%)     3 (100%)     2 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma, Multiple                                                                                 1 (7%)      
      Skin, Site of Application, Keratoacanthoma                                              2 (13%)      2 (13%)      2 (13%)     
      Skin, Site of Application, Keratoacanthoma,                                                                                   
           Multiple                                                                                        1 (7%)       4 (27%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                                           2 (13%)                   2 (13%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma, Multiple                                                                                           1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                    1 (7%)                    4 (27%)      4 (27%)                               
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                                11 (73%)     15 (100%)    13 (87%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Alveolar/Bronchiolar Adenoma                     2 (13%)      1 (7%)                                                          
      Carcinoma, Metastatic, Salivary Glands                        1 (7%)                                                          
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             9           5           9          15          15          13               
     Total Primary Neoplasms                           12           6          12          29          26          32               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  7           5           8          15          15          13               
     Total Benign Neoplasms                             9           5           9          25          23          25               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           1                       3                       5               
     Total Malignant Neoplasms                          1           1                       3                       5               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                          1                                                               
     Total Metastatic Neoplasm                                      1                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  2                       3           1           3           2               
     Total Uncertain Neoplasms                          2                       3           1           3           2               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------